drugset / Trial / NCT00005012

Safety and Effectiveness of PEG-Intron in HIV-Infected Patients

NCT00005012

Phase 2 Completed 250 enrolled Schering-Plough
Treatment

Summary

The purpose of this study is to see if it is effective to give PEG-Intron (PEG-IFN) to HIV-infected patients who are not doing well with their current anti-HIV drug combination (HAART).

Timeline

Start
2000-03
Primary completion
Completion
2000-09

Drugs

EvaluationDrugModalityDoseRoute
Subject Peginterferon alfa-2b Protein / enzyme biologic Subcutaneous